| BIOGEN INC. DL -,0005 | 233.20 / +2.15% |
| Date/Time | 10/25 / 19:35 |
| Chg. / Chg.(%) | 4.90 / +2.15% |
| Bid | 231.70 / 432 |
| Ask | 233.80 / 428 |
| Open | 227.25 |
| Previous Close | 228.30 |
| High | 233.20 |
| Low | 227.25 |
| Volume [EUR] | 0.00 |
| Volume [Units] | 0 |
| Price fixings | 15 |
| ISIN | US09062X1037 |
| Security | IDP |
| Exchange | Berlin |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| NASDAQ | 269.9400 |  |
1,091,711 |
| Cboe US | 269.74 | |
50,525 |
| IEX | 269.99 | |
36,900 |
| London Domes.. | 270.45 | |
1,419 |
| TradeGate | 232.800 | |
1,122 |
| Xetra | 230.25 |  |
587 |
| gettex | 232.600 | |
118 |
| Moscow | 18,856.00 | |
96 |
| Quotrix | 230.0500 | |
58 |
| Frankfurt | 228.0500 | |
35 |
| Vienna Globa.. | 229.95 | |
6 |
| München | 226.85 |  |
0 |
| Hamburg | 226.85 | |
0 |
| Düsseldorf | 233.10 | |
0 |
| Berlin | 233.20 | |
0 |
| Hannover | 226.85 | |
0 |
| Stuttgart | 232.250 | |
0 |
| Lang & Schwa.. | 228.850 | |
|
| Mexico | 5,508.42 | |
25 |
News
- Biogen Q3 revenue down 18% YoY to $2.78B
10/20/2021 / 13:05 - TeleTrader - Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS
10/17/2021 / 22:20 - GlobeNewswire - Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting
10/14/2021 / 22:06 - GlobeNewswire - New Data at ECTRIMS 2021 Highlight Biogen’s Focus on Patient-Centered Outcomes and Improving the MS Patient Experience
10/13/2021 / 12:05 - GlobeNewswire - New MS PATHS Data at ECTRIMS 2021 Confirm Biogen’s Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis
10/13/2021 / 12:02 - GlobeNewswire
Real-time